{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T14:03:23Z","timestamp":1780841003731,"version":"3.54.1"},"reference-count":34,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.ijrobp.2019.02.007","type":"journal-article","created":{"date-parts":[[2019,2,11]],"date-time":"2019-02-11T11:33:10Z","timestamp":1549884790000},"page":"436-446","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Patterns of Failure and Survival Outcomes after Total Lymphoid Irradiation and High-Dose Chemotherapy with Autologous Stem Cell Transplantation for Relapsed or Refractory Classical Hodgkin Lymphoma"],"prefix":"10.1016","volume":"104","author":[{"given":"Nitika","family":"Paudel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"Schulze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan D.","family":"Gentzler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Evens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Helenowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Dillehay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Frankfurt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayesh","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric D.","family":"Donnelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo I.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane N.","family":"Winter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bharat B.","family":"Mittal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2019.02.007_bib1","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1182\/blood.V81.5.1137.1137","article-title":"The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients","volume":"81","author":"Chopra","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.ijrobp.2019.02.007_bib2","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","article-title":"Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: A randomised trial","volume":"359","author":"Schmitz","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2019.02.007_bib3","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/0140-6736(93)92411-L","article-title":"Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: Results of a BNLI randomised trial","volume":"341","author":"Linch","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2019.02.007_bib4","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/0360-3016(95)00180-7","article-title":"Patterns of failure following high-dose chemotherapy and autologous bone marrow transplantation with involved field radiotherapy for relapsed\/refractory Hodgkin's disease","volume":"33","author":"Mundt","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2019.02.007_bib5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0360-3016(96)00277-5","article-title":"High-dose therapy and autologous bone marrow transplantation for relapsed\/refractory Hodgkin's disease: The impact of involved field radiotherapy on patterns of failure and survival","volume":"36","author":"Poen","year":"1996","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2019.02.007_bib6","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.3109\/10428194.2010.486090","article-title":"Long-term results of high-dose chemotherapy with autologous bone marrow or peripheral stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin lymphoma: A single institution experience","volume":"51","author":"Viviani","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ijrobp.2019.02.007_bib7","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1200\/JCO.1993.11.6.1062","article-title":"Accelerated hyperfractionated total-lymphoid irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for refractory and relapsing patients with Hodgkin's disease","volume":"11","author":"Yahalom","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2019.02.007_bib8","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/0360-3016(90)90478-3","article-title":"Improved survival in advanced Hodgkin's disease with the use of combined modality therapy","volume":"19","author":"Brizel","year":"1990","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"10.1016\/j.ijrobp.2019.02.007_bib9","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1111\/bjh.12824","article-title":"F-18 FDG-PET predicts outcomes for patients receiving total lymphoid irradiation and autologous blood stem-cell transplantation for relapsed and refractory Hodgkin lymphoma","volume":"165","author":"Gentzler","year":"2014","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.ijrobp.2019.02.007_bib10","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1093\/annonc\/mdl496","article-title":"Phase I\/II trial of total lymphoid irradiation and high-dose chemotherapy with autologous stem-cell transplantation for relapsed and refractory Hodgkin's lymphoma","volume":"18","author":"Evens","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2019.02.007_bib11","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/bjc.1990.328","article-title":"The Cotswolds report on the investigation and staging of Hodgkin's disease","volume":"62","author":"Crowther","year":"1990","journal-title":"Br J Cancer"},{"issue":"7 suppl 3","key":"10.1016\/j.ijrobp.2019.02.007_bib12","doi-asserted-by":"crossref","first-page":"S1743","DOI":"10.1097\/JTO.0b013e31821ea60c","article-title":"Radiation therapy definitions and reporting guidelines for thymic malignancies","volume":"6","author":"Gomez","year":"2011","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ijrobp.2019.02.007_bib13","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.clml.2015.11.006","article-title":"Trends in use of radiation therapy for Hodgkin lymphoma from 2000 to 2012 on the basis of the National Cancer Data Base","volume":"16","author":"Goyal","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.ijrobp.2019.02.007_bib14","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1200\/JCO.1993.11.12.2342","article-title":"Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: The 21-year Seattle experience","volume":"11","author":"Anderson","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2019.02.007_bib15","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1200\/JCO.1990.8.3.527","article-title":"High-dose cytotoxic therapy and bone marrow transplantation for relapsed Hodgkin's disease","volume":"8","author":"Jones","year":"1990","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2019.02.007_bib16","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.ijrobp.2017.01.222","article-title":"Accelerated total lymphoid irradiation-containing salvage regimen for patients with refractory and relapsed hodgkin lymphoma: 20 years of experience","volume":"97","author":"Rimner","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2019.02.007_bib17","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.ijrobp.2010.10.069","article-title":"Declining use of radiotherapy in stage I and II Hodgkin's disease and its effect on survival and secondary malignancies","volume":"82","author":"Koshy","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2019.02.007_bib18","first-page":"87","article-title":"The prognostic value of 18F-FDG PET-CT in the management of Hodgkin's lymphoma: Preliminary results of a prospective study","volume":"10","author":"Paolini","year":"2007","journal-title":"Nucl Med Rev Cent East Eur"},{"key":"10.1016\/j.ijrobp.2019.02.007_bib19","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1200\/JCO.2007.11.6525","article-title":"Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: A report from a joint Italian-Danish study","volume":"25","author":"Gallamini","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2019.02.007_bib20","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma","volume":"372","author":"Radford","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2019.02.007_bib21","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/bjh.12715","article-title":"The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma","volume":"165","author":"Oki","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ijrobp.2019.02.007_bib22","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11864-015-0360-6","article-title":"Hodgkin lymphoma: The changing role of radiation therapy in early-stage disease-the role of functional imaging","volume":"16","author":"Iberri","year":"2015","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.ijrobp.2019.02.007_bib23","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/S0140-6736(11)61940-5","article-title":"Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): A randomised, open-label, phase 3 non-inferiority trial","volume":"379","author":"Engert","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2019.02.007_bib24","doi-asserted-by":"crossref","first-page":"4934","DOI":"10.1182\/blood-2010-05-282756","article-title":"Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma","volume":"116","author":"Moskowitz","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ijrobp.2019.02.007_bib25","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1093\/annonc\/mdf228","article-title":"The International Prognostic Factors Project score for advanced Hodgkin's disease is useful for predicting outcome of autologous hematopoietic stem cell transplantation","volume":"13","author":"Bierman","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2019.02.007_bib26","first-page":"221","article-title":"New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group","volume":"20","author":"Josting","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2019.02.007_bib27","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/oxfordjournals.annonc.a059242","article-title":"The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin's disease","volume":"6","author":"Ferme","year":"1995","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2019.02.007_bib28","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/sj.bmt.1704789","article-title":"A prognostic model for prolonged event-free survival after autologous or allogeneic blood or marrow transplantation for relapsed and refractory Hodgkin's disease","volume":"35","author":"Hahn","year":"2005","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.ijrobp.2019.02.007_bib29","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","article-title":"Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"385","author":"Moskowitz","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2019.02.007_bib30","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: A multicentre, multicohort, single-arm phase 2 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2019.02.007_bib31","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1470-2045(15)70013-6","article-title":"PET-adapted sequential\u00a0salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: A non-randomised, open-label, single-centre, phase 2 study","volume":"16","author":"Moskowitz","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2019.02.007_bib32","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1182\/blood-2017-10-811224","article-title":"Interim results of brentuximab vedotin in combination with nivolumab in patients with\u00a0relapsed or refractory Hodgkin lymphoma","volume":"131","author":"Herrera","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ijrobp.2019.02.007_bib33","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2017-11-815183","article-title":"Brentuximab vedotin plus bendamustine: A highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma","volume":"132","author":"LaCasce","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ijrobp.2019.02.007_bib34","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N Engl J Med"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S036030161930197X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S036030161930197X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T09:44:45Z","timestamp":1759743885000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S036030161930197X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S036030161930197X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2019.02.007","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patterns of Failure and Survival Outcomes after Total Lymphoid Irradiation and High-Dose Chemotherapy with Autologous Stem Cell Transplantation for Relapsed or Refractory Classical Hodgkin Lymphoma","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2019.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}